A critical goal in heart research is to elucidate the mechanisms that promote clinically significant atherosclerosis and then use this knowledge to design novel therapies. We believe it is essential to couple new concepts with new drug delivery strategies, and we have thus formed a unique multi?PI team with complementary expertise in atherosclerosis and nanomedicine. The overarching concept is that plaque progression represents a pathologic process called defective inflammation resolution. The nanomedicine theme is based on the concept that encapsulation of biologics inside biodegradable, targeted polymeric nanoparticles (NPs) protects the cargo until it is delivered to atheromata and then facilitates controlled release of the biologic. We have demonstrated this principle using a peptide mediator of resolution called Ac2?26. To move closer to human translation, we now propose iterative NP optimization, in?depth mechanistic studies, and application to another type of biologic. The overarching hypothesis is that clinically translatable polymeric NPs packaged with various types of resolution mediators will, via specific molecular mechanisms related to cellular processes of resolution, prevent advanced plaque progression.
In Aim 1, we will iteratively optimize and evaluate collagen IV (Col IV) ? targeted NPs for effective delivery of Ac2?26 to atherosclerotic plaques. Modifications to NP size, charge, loading capacity, and targeting properties will be carried out to increase delivery of bioactive Ac2?26 to atherosclerotic lesions in a manner that optimizes prevention of plaque progression.
In Aim 2, we will elucidate athero?protective mechanisms of Ac2?26 NPs focusing on oxidative stress, collagen formation, defective efferocytosis, and inflammation.
In Aim 3, we will explore the molecular?cellular mechanisms of the pro?resolving protective effects of IL?10 in advanced atherosclerosis using athero? targeted IL?10 NPs, which will be optimized for controlled release kinetics, optimal bioactivity, and efficacy. At the conclusion of this project, we hope t have elucidated mechanistic links between inflammation resolution and atherosclerosis while simultaneously developing nanomedicines capable of blocking plaque progress in high?risk humans.

Public Health Relevance

Atherothrombotic vascular disease is the leading cause of death in the industrialized world, with global spread predicted for the future. Important mechanistic and therapeutic gaps exist in combatting this disease. This proposal will study mechanisms that promote atherosclerosis progression in a manner that is highly translatable to human therapy through the use of nanomedicine.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL127464-04
Application #
9619353
Study Section
Vascular Cell and Molecular Biology Study Section (VCMB)
Program Officer
Lundberg, Martha
Project Start
2016-01-01
Project End
2019-12-31
Budget Start
2019-01-01
Budget End
2019-12-31
Support Year
4
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Columbia University (N.Y.)
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Yu, Mikyung; Amengual, Jaume; Menon, Arjun et al. (2017) Targeted Nanotherapeutics Encapsulating Liver X Receptor Agonist GW3965 Enhance Antiatherogenic Effects without Adverse Effects on Hepatic Lipid Metabolism in Ldlr-/- Mice. Adv Healthc Mater 6:
Fredman, Gabrielle; Tabas, Ira (2017) Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy. Am J Pathol 187:1211-1221
Cai, Bishuang; Thorp, Edward B; Doran, Amanda C et al. (2017) MerTK receptor cleavage promotes plaque necrosis and defective resolution in atherosclerosis. J Clin Invest 127:564-568
Tabas, Ira (2017) 2016 Russell Ross Memorial Lecture in Vascular Biology: Molecular-Cellular Mechanisms in the Progression of Atherosclerosis. Arterioscler Thromb Vasc Biol 37:183-189
Xu, Xiaoding; Saw, Phei Er; Tao, Wei et al. (2017) ROS-Responsive Polyprodrug Nanoparticles for Triggered Drug Delivery and Effective Cancer Therapy. Adv Mater 29:
Xu, Xiaoding; Wu, Jun; Liu, Yanlan et al. (2017) Multifunctional Envelope-Type siRNA Delivery Nanoparticle Platform for Prostate Cancer Therapy. ACS Nano 11:2618-2627
Behzadi, Shahed; Luther, Gaurav A; Harris, Mitchel B et al. (2017) Nanomedicine for safe healing of bone trauma: Opportunities and challenges. Biomaterials 146:168-182
Wang, Ying; Subramanian, Manikandan; Yurdagul Jr, Arif et al. (2017) Mitochondrial Fission Promotes the Continued Clearance of Apoptotic Cells by Macrophages. Cell 171:331-345.e22
DeBerge, Matthew; Yeap, Xin Yi; Dehn, Shirley et al. (2017) MerTK Cleavage on Resident Cardiac Macrophages Compromises Repair After Myocardial Ischemia Reperfusion Injury. Circ Res 121:930-940
Xu, Xiaoding; Saw, Phei Er; Tao, Wei et al. (2017) Tumor Microenvironment-Responsive Multistaged Nanoplatform for Systemic RNAi and Cancer Therapy. Nano Lett 17:4427-4435

Showing the most recent 10 out of 24 publications